In silico investigation of the pharmacological mechanisms of beneficial effects of ginkgo biloba L. On Alzheimer’s disease

Nutrients

Volumn 10, Issue 5, 2018, Pages

  Li, Hongxiang ^a,b   Sun, Xiaoyuan ^a,b   Yu, Fan ^a,b   Xu, Lijia ^a,b   Miu, Jianhua ^a   Xiao, Peigen ^a,b  

^a INSTITUTE OF MEDICINAL PLANT DEVELOPMENT   (China)

^b BEIJING UNIVERSITY OF POSTS AND TELECOMMUNICATIONS   (China)

Author keywords

Alternative therapies; Alzheimer s disease; Dietary supplements; Ginkgo biloba L; Inverse docking; Medicine food homology; Systems pharmacology

Indexed keywords

AMYLOID BETA PROTEIN; ESTROGEN RECEPTOR; GINKGO BILOBA EXTRACT; MEMBRANE METALLOENDOPEPTIDASE; PROTHROMBIN; SERUM ALBUMIN; STROMELYSIN; TAU PROTEIN; THYROID HORMONE; PLANT EXTRACT;

ALTERNATIVE MEDICINE; ALZHEIMER DISEASE; APOPTOSIS; ARTICLE; BIOINFORMATICS; COMPUTER MODEL; DIETARY SUPPLEMENT; DRUG METABOLISM; GENE EXPRESSION; GENE ONTOLOGY; HORMONE SENSITIVITY; HORMONE SYNTHESIS; MOLECULAR DOCKING; NONHUMAN; OXIDATIVE STRESS; PROTEIN AGGREGATION; PROTEIN DEGRADATION; CHEMISTRY; DRUG EFFECT; GINKGO BILOBA; HUMAN; MEDICINAL PLANT; METABOLISM; PHYTOTHERAPY; SIGNAL TRANSDUCTION;

ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; APOPTOSIS; GENE ONTOLOGY; GINKGO BILOBA; HUMANS; MOLECULAR DOCKING SIMULATION; PHYTOTHERAPY; PLANT EXTRACTS; PLANTS, MEDICINAL; SIGNAL TRANSDUCTION; TAU PROTEINS;

EID: 85046879471     PISSN: None     EISSN: 20726643     Source Type: Journal    
DOI: 10.3390/nu10050589     Document Type: Article

References (61)

1. Selkoe, D.J. Preventing Alzheimer’s disease. Science 2012, 337, 1488–1492. [CrossRef] [PubMed]
2. Lleó, A.; Greenberg, S.M.; Growdon, J.H. Current Pharmacotherapy for Alzheimer’s Disease. Ann. Rev. Med. 2006, 57, 513–533. [CrossRef] [PubMed]
3. Selkoe, D.J. Resolving controversies on the path to Alzheimer’s therapeutics. Nat. Med. 2011, 17, 1060. [CrossRef] [PubMed]
4. Wolffram, S.; Ader, P.; Rimbach, G.; Packer, L.; Maguire, J.J.; Schultz, P.G.; Gohil, K. The in vivo Neuromodulatory Effects of the Herbal Medicine Ginkgo Biloba. Proc. Natl. Acad. Sci. USA 2001, 98, 6577.
5. Howes, M.J.; Houghton, P.J. Ethnobotanical treatment strategies against Alzheimer’s disease. Curr. Alzheimer Res. 2012, 9, 67–85. [CrossRef] [PubMed]
6. Chen, Y.Z.; Zhi, D.G. Ligand-protein inverse docking and its potential use in the computer search of protein targets of a small molecule. Proteins Struct. Funct. Bioinform. 2001, 43, 217–226. [CrossRef]
7. Wang, X.; Shen, Y.; Wang, S.; Li, S.; Zhang, W.; Liu, X.; Lai, L.; Pei, J.; Li, H. PharmMapper 2017 update: A web server for potential drug target identification with a comprehensive target pharmacophore database. Nucleic Acids Res. 2017, 45, W356–W360. [CrossRef] [PubMed]
8. Ru, J.; Li, P.; Wang, J.; Zhou, W.; Li, B.; Huang, C.; Li, P.; Guo, Z.; Tao, W.; Yang, Y. TCMSP: A database of systems pharmacology for drug discovery from herbal medicines. J. Cheminform. 2014, 6, 13. [CrossRef] [PubMed]
9. Safran, M.; Dalah, I.; Alexander, J.; Rosen, N.; Stein, T.I.; Shmoish, M.; Nativ, N.; Bahir, I.; Doniger, T.; Krug, H. GeneCards Version 3: The human gene integrator. Database 2010, 2010. [CrossRef] [PubMed]
10. Davis, A.P.; Grondin, C.J.; Lennon-Hopkins, K.; Saraceni-Richards, C.; Sciaky, D.; King, B.L.; Wiegers, T.C.; Mattingly, C.J. The Comparative Toxicogenomics Database’s 10th year anniversary: Update 2015. Nucleic Acids Res. 2015, 43, D914–D920. [CrossRef] [PubMed]
11. Huang, D.W.; Sherman, B.T.; Lempicki, R.A. Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat. Protoc. 2009, 4, 44. [CrossRef] [PubMed]
12. Shannon, P.; Markiel, A.; Ozier, O.; Baliga, N.S.; Wang, J.T.; Ramage, D.; Amin, N.; Schwikowski, B.; Ideker, T. Cytoscape: A software environment for integrated models of biomolecular interaction networks. Genome Res. 2003, 13, 2498–2504. [CrossRef] [PubMed]
13. Shi, C.; Liu, J.; Wu, F.; Yew, D.T. Ginkgo biloba Extract in Alzheimer’s Disease: From Action Mechanisms to Medical Practice. Int. J. Mol. Sci. 2010, 11, 107–123. [CrossRef] [PubMed]
14. Tapan Kumar, M.; Yasinalli, T.; Zubaidha, P.K. Phytochemical and medicinal importance of Ginkgo biloba L. Nat. Prod. Res. 2014, 28, 746–752.
15. Ahlemeyer, B.; Krieglstein, J. Neuroprotective effects of Ginkgo biloba extract. Cell. Mol. Life Sci. 2003, 60, 1779–1792. [CrossRef] [PubMed]
16. Shi, C. Protective effects of Ginkgo biloba extract (EGb761) and its constituents quercetin and ginkgolide B against β-amyloid peptide-induced toxicity in SH-SY5Y cells. Chem. Biol. Interact. 2009, 181, 115–123. [CrossRef] [PubMed]
17. Smith, J.V.; Luo, Y. Studies on molecular mechanisms of Ginkgo biloba extract. Appl. Microbiol. Biotechnol. 2004, 64, 465–472. [PubMed]
18. Maclennan, K.M.; Darlington, C.L.; Smith, P.F. The CNS effects of Ginkgo biloba extracts and ginkgolide B. Prog. Neurobiol. 2002, 67, 235–257. [CrossRef]
19. Smith, J.V.; Luo, Y. Elevation of oxidative free radicals in Alzheimer’s disease models can be attenuated by Ginkgo biloba extract EGb 761. J. Alzheimers Dis. 2003, 5, 287–300. [CrossRef] [PubMed]
20. Bastianetto, S.; Ramassamy, C.; Doré, S.; Christen, Y.; Poirier, J.; Quirion, R. The Ginkgo biloba extract (EGb 761) protects hippocampal neurons against cell death induced by beta-amyloid. Eur. J. Neurosci. 2000, 12, 1882–1890. [CrossRef] [PubMed]
21. 2+-ATPase in human brain affected by Alzheimer’s disease. FASEB J. 2009, 23, 1826–1834. [CrossRef] [PubMed]
22. Yin, Y.; Ren, Y.; Wu, W.; Wang, Y.; Cao, M.; Zhu, Z.; Wang, M.; Li, W. Protective effects of bilobalide on Aβ(25-35) induced learning and memory impairments in male rats. Pharmacol. Biochem. Behav. 2013, 106, 77–84. [CrossRef] [PubMed]
23. Doreulee, N.; Sergeeva, O.A.; Yanovsky, Y.; Chepkova, A.N.; Selbach, O.; Gödecke, A.; Schrader, J.; Haas, H.L. Cortico-striatal synaptic plasticity in endothelial nitric oxide synthase deficient mice. Brain Res. 2003, 964, 159–163. [CrossRef]
24. Austin, S.A.; Santhanam, A.V.; Hinton, D.J.; Choi, D.S.; Katusic, Z.S. Endothelial nitric oxide deficiency promotes Alzheimer’s disease pathology. J. Neurochem. 2013, 127, 691–700. [CrossRef] [PubMed]
25. Austin, S.A.; Santhanam, A.V.; Katusic, Z.S. Endothelial Nitric Oxide Modulates Expression and Processing of Amyloid Precursor ProteinNovelty and Significance. Circ. Res. 2010, 107, 1498–1502. [CrossRef] [PubMed]
26. Haul, S.; Gödecke, A.; Schrader, J.; Haas, H.L.; Luhmann, H.J. Impairment of neocortical long-term potentiation in mice deficient of endothelial nitric oxide synthase. J. Neurophysiol. 1999, 81, 494–497. [CrossRef] [PubMed]
27. Austin, S.A.; D’Uscio, L.V.; Katusic, Z.S. Supplementation of nitric oxide attenuates AβPP and BACE1 protein in cerebral microcirculation of eNOS-deficient mice. J. Alzheimers Dis. 2013, 33, 29–33. [PubMed]
28. Howell, S.; Nalbantoglu, J.; Crine, P. Neutral endopeptidase can hydrolyze β-amyloid(1–40) but shows no effect on β-amyloid precursor protein metabolism. Peptides 1995, 16, 647–652. [CrossRef]
29. Takaki, Y.; Iwata, N.; Tsubuki, S.; Taniguchi, S.; Toyoshima, S.; Lu, B.; Gerard, N.P.; Gerard, C.; Lee, H.J.; Shirotani, K. Biochemical identification of the neutral endopeptidase family member responsible for the catabolism of amyloid beta peptide in the brain. J. Biochem. 2000, 128, 897–902. [CrossRef] [PubMed]
30. Colciaghi, F.; Borroni, B.; Zimmermann, M.; Bellone, C.; Longhi, A.; Padovani, A.; Cattabeni, F.; Christen, Y.; Di, L.M. Amyloid precursor protein metabolism is regulated toward alpha-secretase pathway by Ginkgo biloba extracts. Neurobiol. Dis. 2004, 16, 454–460. [CrossRef] [PubMed]
31. Baker, L.D.; Cross, D.J.; Minoshima, S.; Belongia, D.; Watson, G.S.; Craft, S. Insulin resistance and Alzheimer-like reductions in regional cerebral glucose metabolism for cognitively normal adults with prediabetes or early type 2 diabetes. Arch. Neurol. 2011, 68, 51–57. [CrossRef] [PubMed]
32. Subhadra, B.; Schaller, K.; Seeds, N.W. Neuroserpin up-regulation in the Alzheimer’s disease brain is associated with elevated thyroid hormone receptor-β1 and HuD expression. Neurochem. Int. 2013, 63, 476–481. [CrossRef] [PubMed]
33. Yan, R.; Vassar, R. Targeting the β secretase BACE1 for Alzheimer’s disease therapy. Lancet Neurol. 2014, 13, 319–329. [CrossRef]
34. Vassar, R.; Kovacs, D.M.; Yan, R.; Wong, P.C. The β-Secretase Enzyme BACE in Health and Alzheimer’s Disease: Regulation, Cell Biology, Function, and Therapeutic Potential. J. Neurosci. 2009, 29, 12787–12794. [CrossRef] [PubMed]
35. White, H.L.; Scates, P.W.; Cooper, B.R. Extracts of Ginkgo biloba leaves inhibit monoamine oxidase. Life Sci. 1996, 58, 1315–1321. [CrossRef]
36. Pardon, M.C.; Joubert, C.; Perez-Diaz, F.; Christen, Y.; Launay, J.M.; Cohen-Salmon, C. In vivo regulation of cerebral monoamine oxidase activity in senescent controls and chronically stressed mice by long-term treatment with Ginkgo biloba extract (EGb 761). Mech. Aging Dev. 2000, 113, 157–168. [CrossRef]
37. Chaurasiya, N.D.; Ganesan, S.; Nanayakkara, N.P.; Dias, L.R.; Walker, L.A.; Tekwani, B.L. Inhibition of human monoamine oxidase A and B by 5-phenoxy 8-aminoquinoline analogs. Bioorg. Med. Chem. Lett. 2012, 22, 1701–1704. [CrossRef] [PubMed]
38. Aliev, G.; Seyidova, D.; Lamb, B.T.; Obrenovich, M.E.; Siedlak, S.L.; Vinters, H.V.; Friedland, R.P.; Lamanna, J.C.; Smith, M.A.; Perry, G. Mitochondria and vascular lesions as a central target for the development of Alzheimer’s disease and Alzheimer disease-like pathology in transgenic mice. Neurol. Res. 2003, 25, 665–674. [CrossRef] [PubMed]
39. Biere, A.L.; Ostaszewski, B.; Stimson, E.R.; Hyman, B.T.; Maggio, J.E.; Selkoe, D.J. Amyloid beta-peptide is transported on lipoproteins and albumin in human plasma. J. Biol. Chem. 1996, 271, 32916–32922. [CrossRef] [PubMed]
40. Li, G.H.; Arora, P.D.; Chen, Y.; Mcculloch, C.A.; Liu, P. Multifunctional roles of gelsolin in health and diseases. Med. Res. Rev. 2012, 32, 999–1025. [CrossRef] [PubMed]
41. Atwood, C.S.; Meethal, S.V.; Liu, T.; Wilson, A.C.; Gallego, M.; Smith, M.A.; Bowen, R.L. Dysregulation of the hypothalamic-pituitary-gonadal axis with menopause and andropause promotes neurodegenerative senescence. J. Neuropathol. Exp. Neurol. 2005, 64, 93–103. [CrossRef] [PubMed]
42. Meethal, S.V.; Smith, M.A.; Bowen, R.L.; Atwood, C.S. The gonadotropin connection in Alzheimer’s disease. Endocrine 2005, 26, 317–325. [CrossRef]
43. Pedrós, I.; Petrov, D.; Artiach, G.; Abad, S.; Ramon-Duaso, C.; Sureda, F.; Pallàs, M.; Beas-Zarate, C.; Folch, J.; Camins, A. Adipokine pathways are altered in hippocampus of an experimental mouse model of Alzheimer’s disease. J. Nutr. Health Aging 2015, 19, 403–412. [CrossRef] [PubMed]
44. Dye, R.V.; Miller, K.J.; Singer, E.J.; Levine, A.J. Hormone Replacement Therapy and Risk for Neurodegenerative Diseases. Int. J. Alzheimers Dis. 2012, 2012, 258454. [CrossRef] [PubMed]
45. Long, J.; He, P.; Shen, Y.; Li, R. New evidence of mitochondria dysfunction in the female Alzheimer’s brain: Deficiency of estrogen receptor-β. J. Alzheimers Dis. 2012, 30, 545–558. [PubMed]
46. Jackson, H.M.; Soto, I.; Graham, L.C.; Carter, G.W.; Howell, G.R. Clustering of transcriptional profiles identifies changes to insulin signaling as an early event in a mouse model of Alzheimer’s disease. BMC Genom. 2013, 14, 831. [CrossRef] [PubMed]
47. Burbach, J.P.; Voorhuis, T.A.; van Tol, H.H.; Ivell, R. In situ hybridization of oxytocin messenger RNA: Macroscopic distribution and quantitation in rat hypothalamic cell groups. Biochem. Biophys. Res. Commun. 1987, 145, 10–14. [CrossRef]
48. Hollowell, J.G.; Staehling, N.W.; Flanders, W.D.; Hannon, W.H.; Gunter, E.W.; Spencer, C.A.; Braverman, L.E. Serum TSH, T(4), and thyroid antibodies in the United States population (1988 to 1994): National Health and Nutrition Examination Survey (NHANES III). J. Clin. Endocr. Metab. 2002, 87, 489–499. [CrossRef] [PubMed]
49. Riederer, P.; Bartl, J.; Laux, G.; Grünblatt, E. Diabetes type II: A risk factor for depression-Parkinson-Alzheimer? Neurotox. Res. 2011, 19, 253–265. [CrossRef] [PubMed]
50. Huang, S.M.; Mouri, A.; Kokubo, H.; Nakajima, R.; Suemoto, T.; Higuchi, M.; Staufenbiel, M.; Noda, Y.; Yamaguchi, H.; Nabeshima, T. Neprilysin-sensitive synapse-associated amyloid-beta peptide oligomers impair neuronal plasticity and cognitive function. J. Biol. Chem. 2006, 281, 17941–17951. [CrossRef] [PubMed]
51. Zhao, L.; Yao, J.; Mao, Z.; Chen, S.; Wang, Y.; Brinton, R.D. 17β-Estradiol regulates insulin-degrading enzyme expression via an ERβ/PI3-K pathway in hippocampus: Relevance to Alzheimer’s prevention. Neurobiol. Aging 2011, 32, 1949–1963. [CrossRef] [PubMed]
52. Wang, L.; Andersson, S.; Warner, M.; Gustafsson, J.A. Morphological abnormalities in the brains of estrogen receptor beta knockout mice. Proc. Natl. Acad. Sci. USA 2001, 98, 2792–2796. [CrossRef] [PubMed]
53. Waters, E.M.; Yildirim, M.; Janssen, W.G.M.; Lou, W.Y.W.; Mcewen, B.S.; Morrison, J.H.; Milner, T.A. Estrogen and aging affect the synaptic distribution of estrogen receptor α-immunoreactivity in the CA1 region of female rat hippocampus. Brain Res. 2011, 1379, 86–97. [CrossRef] [PubMed]
54. Zhao, L.; Mao, Z.; Schneider, L.S.; Brinton, R.D. Estrogen receptor β-selective phytoestrogenic formulation prevents physical and neurological changes in a preclinical model of human menopause. Menopause 2011, 18, 1131–1142. [CrossRef] [PubMed]
55. Kalgutkar, A.S.; Dalvie, D.K., Jr.; Castagnoli, N.; Taylor, T.J. Interactions of nitrogen-containing xenobiotics with monoamine oxidase (MAO) isozymes A and B: SAR studies on MAO substrates and inhibitors. Chem. Res. Toxicol. 2001, 14, 1139–1162. [CrossRef] [PubMed]
56. Arai, T.; Miklossy, J.; Klegeris, A.; Guo, J.P.; Mcgeer, P.L. Thrombin and prothrombin are expressed by neurons and glial cells and accumulate in neurofibrillary tangles in Alzheimer disease brain. J. Neuropathol. Exp. Neurol. 2006, 65, 19–25. [CrossRef] [PubMed]
57. Era, S.; Kuwata, K.; Imai, H.; Nakamura, K.; Hayashi, T.; Sogami, M. Age-related change in redox state of human serum albumin. Biochim. Biophys. Acta 1995, 1247, 12–16. [CrossRef]
58. Guerin-Dubourg, A.; Catan, A.; Bourdon, E.; Rondeau, P. Structural modifications of human albumin in diabetes. Diabetes Metab. 2012, 38, 171–178. [CrossRef] [PubMed]
59. Johansson, P.; Almqvist, E.G.; Johansson, J.O.; Mattsson, N.; Hansson, O.; Wallin, A.; Blennow, K.; Zetterberg, H.; Svensson, J. Reduced cerebrospinal fluid level of thyroxine in patients with Alzheimer’s disease. Psychoneuroendocrinology 2013, 38, 1058–1066. [CrossRef] [PubMed]
60. Ray, I.; Chauhan, A.; Wegiel, J.; Chauhan, V. Gelsolin inhibits the fibrillization of amyloid beta-protein, and also defibrillizes its preformed fibrils. Brain Res. 2000, 853, 344–351. [CrossRef]
61. Hirko, A.C.; Meyer, E.M.; King, M.A.; Hughes, J.A. Peripheral Transgene Expression of Plasma Gelsolin Reduces Amyloid in Transgenic Mouse Models of Alzheimer’s Disease. Mol. Ther. J. Am. Soc. Gene Ther. 2007, 15, 1623–1629. [CrossRef] [PubMed]